

REMARKS

The allowance of claims 17-29 is respectfully acknowledged.

The Amendments

The "use" claims 1-13 are canceled and replaced with new method claims 30-42. Support for the method is found in the original claims and at page 1, lines 8-10, page 5, line 25, to page 6, line 4, of the specification, for example. The composition claims 14-16 are replaced with new composition claims 43-44. These claims require the preferred component of formulae IIID or IIIE from the broader formulae III-VII (see, e.g., page 27, lines 27-28, for support of this preference). Claim 43 further recites a combination of compounds of formulae I and II and support therefore is found, for example, at page 19, line 3, of the specification. Claim 44 requires the formula VIII compound as supported by previous dependent claim 16. These composition claims also recite some amount requirements. Support for these recitations is found in the specification, for example, at page 19, lines 9-14, page 34, line 11, and page 39, line 17.

The amendments do not narrow the scope of the broadest device or method of use claims. To the extent that the amendments avoid the prior art or for other reasons related to patentability, competitors are warned that the amendments are not intended to and do not limit the scope of equivalents which may be asserted on subject matter outside the literal scope of any patented claims but not anticipated or rendered obvious by the prior art or otherwise unpatentable to applicants. Applicants reserve the right to file one or more continuing and/or divisional applications directed to any subject matter disclosed in the application which has been canceled by any of the above amendments.

The Rejections under 35 U.S.C. §112 and §101

The rejections under 35 U.S.C. §112 and §101 are rendered moot by the cancellation of the "use" claims.

The Rejections under 35 U.S.C. §102


The rejections of claims 14-16 under 35 U.S.C. §102, as being anticipated by both Kojima (U.S. Patent No. 6,440,506) and Weber (U.S. Patent No. 6,028,655) are respectfully traversed.

The references do not disclose specific compositions which contain a compound according to applicants' formula II (now recited in both composition claims 43 and 44). Compare the definition of R²¹ in the instant claims. The reference components MEnN.F, HPnN.F and CCPC-nm do not contain a terminal alkenyl group and the HP and CCPC compounds are not two ring compounds. Also, the other components listed in the Office Action from the specifically pointed out reference examples do not meet applicants' formula II. Furthermore, the references fail to disclose or suggest a particular composition combining the components as recited in composition claims 43 and 44 in the amounts recited.

At least for these reasons, claims 43 and 44 are not anticipated by Kojima or Weber and the rejections under 35 U.S.C. §102 should be withdrawn.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



John A. Sopp, Reg. No. 33,103
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3035

Date: August 18, 2006

JAS/blb

K:\Merck\3000 - 3999\3035\amendment 8-18-06.doc